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CTLA-4 has long been associated
with control of autoimmunity. A
recent study by Sharpe and760 Trends in Immunology, December 2015, Vol. 36, No. 1colleagues explores this relation-
ship in a model that enables con-
ditional deletion of CTLA-4 in adult
mice, with some surprising new
conclusions.CTLA-4 is one of a small number of immune
genes whose deletion triggers fatal lym-
phoproliferative disease. Its importance in
immune regulation is unquestioned; how-
ever, its precise mechanism of action has
been hotly debated. In a recent paper in
The Journal of Experimental Medicine [1]
the Sharpe laboratory, who originally
reported the phenotype of CTLA-4 null
mice, brings us another intriguing install-
ment in the CTLA-4 story. By generating
mice with a ﬂoxed CTLA-4 allele, and
crossing them to mice expressing a tamox-
ifen inducible Cre-recombinase, the
authors constructed an experimental sys-
tem in which CTLA-4 could be ablated ‘at
will’ by tamoxifen administration. This per-
mits for the ﬁrst time the deletion of the
CTLA-4 gene only in adult mice.
The ﬁrst surprise in the data is that punc-
tual ablation of the CTLA-4 gene in 7-week
old mice failed to trigger spontaneous
autoimmunity, contrasting with the situa-
tion following germline deletion. Further-
more, the CTLA-4-deleted mice exhibited
reduced susceptibility to MOG-induced
experimental autoimmune encephalomy-
elitis (EAE) and did not exhibit an increased
capacity to clear tumors, both opposite to
expectations based on the concept that
CTLA-4 inhibits autoimmunity and limits
anti-tumor responses.
So what is the basis for these striking
ﬁndings? By breeding the tamoxifen delet-
able CTLA-4 mice to a MOG-speciﬁc TCR
transgenic mouse (2D2) the authors ﬁrst
homed in on the role of CTLA-4 in
conventional T (Tconv) cells. Adoptively
transferred 2D2 T cells induced EAE in
RAG-deﬁcient mice with similar onset
and severity regardless of whether these
cells expressed CTLA-4 or not. An elegant
approach in which CTLA-4 was deleted2from IL-17 expressing cells T cells (IL-17F-
Cre) also revealed no difference in EAE
incidence. Next, adoptive transfer experi-
ments were performed in which both T
regulatory (Treg) cells and Tconv cells
were injected into recipient mice, but
CTLA-4 deﬁciency was restricted to
the latter: these experiments revealed a
subtle increase in Tconv cell number in
the absence of CTLA-4, although prolifer-
ative responses to MOG peptide or anti-
CD3 and cytokine differentiation in vitro
were not altered. Thus, CTLA-4 deﬁciency
in the Tconv compartment had small but
discernable biological consequences;
however, it did not alter EAE induction.
By contrast, deletion of CTLA-4 from the
Treg compartment was sufﬁcient to reca-
pitulate the effects of systemic CTLA-4
deletion, with similar protection from
EAE being observed. Thus in keeping with
many other experimental settings, the
major role of CTLA-4 was shown to be
in Treg cells; however, unexpectedly this
resulted in disease protection rather than
disease exacerbation.
In keeping with previous work, the authors
observed a dramatic expansion of the
Treg cell population in CTLA-4-deleted
mice, reﬂecting a marked increase in their
proliferation (60% Treg cells were Ki67+
in CTLA-4-deleted mice as compared to
30% in controls) [1]. This nicely parallels
the increased Treg cell proliferation seen in
mice lacking CTLA-4 from birth (62%
Treg were Ki67+ in CTLA-4/ mice com-
pared with 28% in littermate controls)
[2]. By ablating CTLA-4 speciﬁcally in
the Treg compartment, using a tamoxi-
fen-inducible cre under the control of
the Foxp3 promoter, the authors were
able to conﬁrm that the Treg cell expan-
sion was a direct effect of CTLA-4 in the
Treg cells themselves. As the authors sur-
mise, this Treg cell expansion following
CTLA-4 ablation likely reﬂects unre-
strained CD28 signaling, since CTLA-4
is known to compete with CD28 for
access to their shared ligands CD80
and CD86.
It has been shown previously that
CTLA-4/ Treg cells can exhibit a com-
pensatory overproduction of both IL-10
and TGF-b [3]. Indeed, the Powrie group
demonstrated that while suppression of
colitis by wild type Treg cells was CTLA-
4 dependent, CTLA-4/ Treg cells were
able to use IL-10 to elicit suppression [4],
providing a precedent for the compensa-
tion of CTLA-4 function by the IL-10 path-
way. Data presented by Paterson and
colleagues suggest that a similar situation
may arise following inducible deletion of
CTLA-4: In the context of the EAE model,
CTLA-4 ablation was associated with a
marked increase in the proportion of Treg
cells producing IL-10. The functional
impact of this could be potentiated by
the greater than 3 fold increase in the
absolute numbers of Treg cells. Thus,
although most of these Treg cells could
no longer use CTLA-4, the population was
expanded in number and had an
enhanced capacity to produce IL-10
(Figure 1). NanoString transcriptional anal-
ysis conﬁrmed that the Treg cells adopted
a gene expression signature associated
with high IL-10 production, including
increased expression of the transcriptionTreg
IL
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Tr1 cells.factor Blimp-1. Therefore, one explanation
for the paradoxical disease protection fol-
lowing CTLA-4 ablation could be the
altered cytokine environment imposed
by an expanded population of Treg cells
that overproduce IL-10.
The authors next set out to test whether
CTLA-4- ablated Treg cells had the
capacity to elicit suppressive function.
They ﬁrst employed in vitro suppression
assays, and demonstrated equivalent
suppressive function regardless of
whether the Treg cells derived from
tamoxifen-treated (hence CTLA-4-
ablated) animals. This result is not entirely
unexpected, since several groups have
found that CTLA-4/ Treg cells exhibit
intact suppression in such in vitro assays
[2,3,5]. Moving to an in vivo setting, the
authors went on to show that CTLA-4-
ablated Treg cells retained the capacity
to control the homeostatic proliferation
of T cells adoptively transferred to Rag-
deﬁcient recipients. This contrasts with the
ﬁndings of Sojka et al. [5] who showed that
CTLA-4/ Treg were impaired in their
capacity to control lymphopenia-induced
T cell expansion. This could reﬂect aTreg Treg
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focused on CD62L+Treg cells. Alterna-
tively, it might reﬂect residual CTLA-4
activity resulting from incomplete gene
deletion in the tamoxifen system.
Curiously, despite conferring protection
from EAE, loss of CTLA-4 from Treg cells
triggered a signiﬁcant expansion of Tconv
cells in the cervical lymph nodes, with more
cells expressing ki67 and bearing a
CD44hiCD62Llo phenotype, consistent with
a role for Treg cells in suppressing Tconv cell
activation via CTLA-4. However, if Tconv
cell responses are unleashed following Treg
cell CTLA-4 ablation, why then is this asso-
ciated with disease protection? One possi-
bility is that although Tconv cells become
activated, they differentiate in a manner that
leads them to be non-pathogenic, at least in
EAE. Alterations in T cell cytokine produc-
tion are known to affect the disease course
in the EAE model, sometimes in unexpected
ways. For example increases in one cyto-
kine (e.g., IFNg) can lead to decreases in
another (e.g., IL-17) and consequent dis-
ease suppression. Paterson et al. showed
that these Tconv cells exhibited higher levelsTreg
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Treg
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of Ebi3, a subunit of the cytokine IL-27,
which is known to inhibit Th17 differentiation
and suppress EAE [6]. IL-27 is also recog-
nized for its role in promoting the formation
of type 1 regulatory T (Tr1) cells [6], and it is
notable that amounts of several typical Tr1
products are increased in the Tconv cells
(e.g., IL-10, Ahr, ICOS, LAG3). Thus one
could envisage the expanded population of
IL-10-producing Treg cells providing a
favorable environment for induction of Tr1
cells that might in turn contribute to disease
protection.
When the authors crossed the mice
expressing a ﬂoxed CTLA-4 allele with
mice bearing Foxp3-cre, this recapitulated
the lethal phenotype reported by others
[7], illustrating that CTLA-4 deﬁciency
restricted to the Treg compartment is suf-
ﬁcient to cause fatal disease. Given that
inducible CTLA-4 deletion in adult mice (in
all cells or only in Treg cells) did not elicit
disease, the authors suggest there may be
a critical window of time developmentally
during which CTLA-4 expression in Treg
cells is essential. This could, for example,
reﬂect a need for CTLA-4 during the neo-
natal period that diminishes once the
peripheral immune compartment is fully
seeded. Arguing against the need for
CTLA-4 solely in the neonatal period is
the observation that mixed bone marrow
chimeras, comprising CTLA-4/ and wild
type cells, rapidly become sick if the wild
type cells are deleted during adulthood [8].
Such a hypothesis is also hard to reconcile
with the studies that demonstrate defec-
tive function of CTLA-4/ Treg cells in762 Trends in Immunology, December 2015, Vol. 36, No. 1adoptive transfer models, which typically
use adult donors and recipients. A com-
prehensive comparison between condi-
tional CTLA-4 deletion in neonates
versus adult mice will be important in
exploring this hypothesis further.
An alternative explanation for the lack of
disease following ablation of CTLA-4 in
adult mice could relate to the efﬁciency
of tamoxifen-driven gene excision in Treg
cells, Tconv cells and their precursors. For
example,  7% of Treg cells still
expressed CTLA-4 after tamoxifen treat-
ment, and it is possible that these con-
tribute to the observed lack of
autoimmune disease. Incomplete dele-
tion of CTLA-4 could potentially mirror
the situation in humans with heterozy-
gous CTLA-4 deﬁciency [9,10], some of
whom are asymptomatic. Intriguingly,
quantitative defects in CTLA-4 in humans
are associated with signiﬁcant expansion
of the Treg cell compartment [9], and it is
tempting to speculate that protection
from autoimmunity in asymptomatic indi-
viduals results from compensatory mech-
anisms such as the overproduction of IL-
10 reported here. Notably the autoim-
mune phenotype in symptomatic individ-
uals with CTLA-4 heterozygosity
manifests relatively late in life, contrasting
with the early onset associated with
Foxp3 deﬁciency in IPEX. It will be of great
interest to track the status of CTLA-4-
ablated mice during aging and following
a variety of immunological challenges to
gain a broader perspective on the role of
CTLA-4 in different contexts. Meanwhile,2the increasingly reﬁned tools being used
to unravel the biology of this critical
immune regulator will doubtless continue
to turn up new surprises.
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